Abcam, ab263244, Human LGALS9C knockout A549 cell lysate

Size: 1Kit
LGALS9C KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon3 and 4 bp deletion in exon3 and 4 bp insertion in exon3 and 8 bp deletion in exon3.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon3 and 4 bp deletion in exon3 and 4 bp insertion in exon3 and 8 bp deletion in exon3.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LGALS9C, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LGALS9C also known as Galectin-9c belongs to the galectin family which mediates cell-cell interactions cell-matrix adhesion and apoptotic pathways. This protein has a molecular mass of approximately 36 kDa. You can find it expressed in various tissues with notable presence in immune cells suggesting a role in immune system regulation. Researchers often associate other names such as Gal-9S and Galectin-9c Isoform with this protein indicating its various isoforms adapt functions in different cells.
Biological function summary
LGALS9C influences immune response modulation highlighting its presence in immune cell function. It interacts with biologically significant partners often forming a complex with receptors like Tim-3 on T cells. This interaction can either promote cell death in certain contexts or drive anti-inflammatory responses. The involvement of LGALS9C in regulating the survival and function of these cells underlines its importance in maintaining homeostasis within the immune system.
Pathways
LGALS9C plays significant roles within immune signaling pathways including the Tim-3/Galectin-9 pathway. It also intersects with the apoptosis regulatory pathway influencing cellular outcomes during immune responses. LGALS9C interacts with proteins such as Tim-3 and PD-1 which share pathways that regulate immune responses and tolerance. The modulation of immune checkpoints places LGALS9C within a network of pathways that could influence therapy in chronic inflammation and cancer.
LGALS9C shows relevance to autoimmune diseases and cancer. It has been observed to dysregulate inflammatory responses contributing to conditions like systemic lupus erythematosus (SLE). During cancer progression LGALS9C can affect tumor microenvironment by interacting with proteins such as Tim-3 and influencing immune evasion mechanisms. These connections make LGALS9C a target of interest for therapeutic interventions aiming to modulate immune responses in disease treatment.